3′-deoxy-3′-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy
In patients with advanced NSCLC who achieved a tumor response, proliferation decreased in the bone marrow, but not in the spleen or lymph nodes, 6 weeks after treatment initiation. <sup>18</sup>F-FLT PET can help monitor changes in tumor immunity in each lymphoid tissue and may serve as a biomarker for the response to immune checkpoint inhibitor therapy.
Authors
- Masayuki Sato (ORCID: https://orcid.org/0000-0002-0213-3187)
- Hidehiko Okazawa (ORCID: https://orcid.org/0000-0001-7046-3383)
- Yuko Waseda (ORCID: https://orcid.org/0000-0002-7120-8517)
- Chisato Honjo
- Tomoaki Sonoda
- Tamotsu Ishizuka (ORCID: https://orcid.org/0000-0002-8347-3553)
- Tetsuya Tsujikawa (ORCID: https://orcid.org/0000-0002-8980-1044)
- Yukihiro Umeda (ORCID: https://orcid.org/0000-0002-9826-6856)
- Tetsuya Mori (ORCID: https://orcid.org/0000-0001-5347-8890)
- Akikazu Shimada
- Makiko Yamaguchi
- Yasushi Kiyono
Institutions
- University of Fukui (JP)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1186/s13550-025-01225-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00